Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease

American Journal of Industrial Medicine

Volumn 43, Issue 6, 2003, Pages 592-601

  Maier, Lisa A ^a,b   Kittle, Lori A ^a   Mroz, Margaret M ^a   Newman, Lee S ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Berylliosis; Beryllium; Biomarker; Chronic beryllium disease; Diagnosis; Neopterin

Indexed keywords

BERYLLIUM; BERYLLIUM SULFATE; NEOPTERIN;

ADULT; ARTICLE; BERYLLIOSIS; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; EXERCISE TEST; FEMALE; GAS EXCHANGE; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; SARCOIDOSIS; SENSITIZATION; THORAX RADIOGRAPHY;

ADULT; BERYLLIOSIS; BERYLLIUM; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEOPTERIN; OCCUPATIONAL EXPOSURE; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS, PULMONARY; SENSITIVITY AND SPECIFICITY;

EID: 0038486001     PISSN: 02713586     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajim.10227     Document Type: Article

References (41)

1. Altindag ZZ, Sahin G, Inanici F, Hascelik Z. 1998. Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis. Rheumatol Int 18:107-111.
2. American Thoracic Society (ATS). 1999. The European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Joint Statement on Sarcoidosis. Am J Respir Crit Care Med 160:736-755.
3. Blaschke E, Eklund A, Persson U. 1988. Relationship between serum neopterin and lymphocytic alveolitis in sarcoidosis. Sarcoidosis 5: 25-30.
4. Crapo RO, Morris AH. 1981. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 123: 185-189.
5. Eklund A, Blaschke E. 1986. Elevated serum neopterin levels in sarcoidosis. Lung 164:325-332.
6. Ferris BG, Jr., Higgins IT, Higgins MW, Peters JM, Van Ganse WF, Goldman MD. 1971. Chronic nonspecific respiratory disease, Berlin, New Hampshire, 1961-1967: A cross-sectional study. Am Rev Respir Dis 104:232-244.
7. Goldman HI, Becklake MR. 1959. Respiratory function tests: Normal values at medium altitudes and the prediction of normal results. Am Rev Tuber 79:457.
8. Hamerlinck F. 1999. Neopterin: A review. Exp Dermatol 8:167-176.
9. Harris J, Bucher Bartelson B, Barker E, Balkissoon R, Kreiss K, Newman LS. 1997. Serum neopterin in chronic beryllium disease. Am J Ind Med 32:21-26.
10. Henneberger PK, Cumro D, Deubner DD, Kent MS, McCawley M, Kreiss K. 2001. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 74:167-176.
11. Huber C, Fuchs D, Hausen A, Margreiter R, Reibnegger G, Spielberger M, Wachter H. 1983. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol 130:1047-1050.
12. Huber C, Batchelor JR, Fuchs D, Hausen A, Reibnegger G, Specks B, Wachter H. 1984. Immune response-associated production of neopterin: Release from macrophages primarily under control of interferon-gamma. J Exp Med 160:310-316.
13. Immanuel C, Swamy R, Kannapiran M, Vijayalakshmi S, Sundaram V, Jagannath K, Paramasivan CN. 1997. Neopterin as a marker for cell-mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 1:175-180.
14. International Labor Organization. 1980. Guidelines for the Use of ILO International Classification of Radiographs of Pneumoconioses Geneva, Switzerland: International Labour Office.
15. Kreiss K, Wasserman S, Mroz MM, Newman LS. 1993a. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 35:267-274.
16. Kreiss K, Mroz MM, Zhen B, Martyny J, Newman LS. 1993b. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 148:985-991.
17. 3. Am J Ind Med 30:16-25.
18. Lacronique J, Auzeby A, Valeyre D, Traore BM, Barbosa MLA, Soler P, Choudat D, Battesti JP, Touitous Y, Marsac J. 1989. Urinary neopterin in pulmonary sarcoidosis: Relationship to clinical and biological assessment of the disease. Am Rev Respir Dis 139:1474-1478.
19. Lim KL, Muir K, Powell RJ. 1994. Urine neopterin: A new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 53:743-748.
20. Maier LA. 2001. Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 16:514-520.
21. Maier LA, Barker EA, Raynolds MV, Newman LS. 1999. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med 159:1342-1350.
22. Maier L, Kittle L, Mroz M, Newman L. 2000. Neopterin and IFN-γ as diagnostic adjuncts in chronic beryllium disease. Am J Resp Crit Care Med 161:A731.
23. Maier LA, Sawyer RT, Tinkle SS, Kittle LA, Barker EA, Balkissoon R, Rose C, Newman LS. 2001. IL-4 fails to regulate in vitro beryllium-induced cytokines in berylliosis. Eur Respir J 17:403-415.
24. Mohamed KH, Mobasher AA, Yousef AR, Salah A, El-Naggar IZ, Ghoneim AH, Light RW. 2001. BAL neopterin: A novel marker for cell-mediated immunity in patients with pulmonary tuberculosis and lung cancer. Chest 119:776-780.
25. Morris AH, Kanner RE, Crapo RO, Gardner RM. 1984. Clinical pulmonary function testing: A manual of uniform laboratory procedures. 2nd edition. Salt Lake City: Intermountain Thoracic Society. pp 154-155.
26. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. 1991. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 88: 54-60.
27. Newman LS, Bobka C, Schumacher B, Daniloff E, Zhen B, Mroz MM, King TE, Jr. 1994. Compartmentalized immune response reflects clinical severity of beryllium disease. Am J Respir Crit Care Med 150: 135-142.
28. Newman LS, Balkissoon R, Daniloff E, Solida M, Mroz M. 1998. Rate of progression from beryllium sensitization to chronic beryllium disease is 9-19% per year. Am J Respir Crit Care Med 157:A145.
29. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. 2001. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J Occup Environ Med 43: 231-237.
30. Ogilvie CM, Forster RE, Blakemore WS, Morton JW. 1956. A standardized breathholding technique for the clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 36: 1-17.
31. Pappas GP, Newman LS. 1993. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 148:661-666.
32. Prior C, Frank A, Fuchs D, Hausen A, Judmaier G, Reibnegger G, Wemer ER, Wachter H. 1988. Urinary neopterin excretion in pulmonary sarcoidosis: Correlation to clinical course of the disease. Clin Chim Acta 177:211-220.
33. Stange AW, Hilmas DE, Furman FJ. 1996. Possible health risks from low level exposure to beryllium. Toxicology 111:213-224.
34. Tinkle SS, Newman LS. 1997. Beryllium-stimulated release of tumor necrosis factor-alpha, interleukin-6, and their soluble receptors in chronic beryllium disease. Am J Respir Crit Care Med 156:1884-1891.
35. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. 1997. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 158:518-526.
36. Troppmair J, Nachbaur K, Herold M, Aulitzky W, Tilg H, Gastl G, Bieling P, Kotlan B, Flener R, Mull B, Aulitzky WO, Rokos H, Huber CH. 1988. In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens, and lipopolysaccharide (LPS). Clin Exp Immunol 74:392-397.
37. Watters LC, Schwarz MI, Cherniack RM, Waldron JA, Dunn TL, Stanford RE, King TE. 1987. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 135:696-704.
38. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, Fuchs D. 1999. Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells. Clin Exp Immunol 116:435-440.
39. Werner-Felmayer G, Werner ER, Fuchs D, Hausen A, Reibnegger G, Wachter H. 1990. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res 50:2863-2867.
40. Willcox M, Kervitsky A, Watters LC, King TE, Jr. 1988. Quantification of cells recovered by bronchoalveolar lavage: Comparison of cytocentrifuge preparations with the filter method. Am Rev Respir Dis 138: 74-80.
41. Woloszczuk W, Schwarz M, Havel M, Laczkovics A, Muller M. 1986. Neopterin and interferon gamma serum levels in patients with heart and kidney transplants. J Clin Chem Clin Biochem 24:729-734.